ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

Hemepath Master Class: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Hemepath Master Class: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

This on-demand webinar will discuss:

? -? The background of CLL/SLL

? -? Diagnostic criteria

? -? Prognostic markers

? -? A case study

?

?

This is a recording from a live webinar series in collaboration with The US Oncology Network (USON) that was held in the beginning of 2023.

?

Date:
Mar 16, 2023
Presenter(s):

Hope Karnes, MD, PhD, FASCP, FCAP,

Medical Director Clinical Solutions, Quest Diagnostics

Moderator(s):

Hilary Frayer,?BS, CG(ASCP)cm, MB(ASCP) cm

Product Director, Hematopathology, Quest Diagnostics

Related content

On-Demand Webinar
Innovations within Precision Oncology Evolution of a Biomarker a Case Study of KRAS-G12C
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
On-Demand Webinar
Unwinding with DDX41 A case presentation regarding DDX41 and its germline predisposition to myeloid neoplasms
Audio Podcast
Optimize Oncology Care with Clinical Pathways
On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care
On-Demand Webinar
Quality Considerations for Mobile Blood Draws and Specimen Collections: Supporting Decentralized Studies and Trials

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.